

## **REMARKS**

### **Claim Amendment**

Claim 1 has been amended to delete the two instances of “optionally contain one or more O, S or NR4 groups” from the claim. In addition, in claim 1, X is now “N or NH,” support of which can be found in the original claim 1. The term “cysteine protease” has been inserted after the words “at least one” in Claims 11 and 15 in order to improve their readability. The support for this amendment can be found at lines 14-15 of page 1 of the original specification.

### **35 U.S.C. §112**

Claims 1-3 and 10-13 were rejected by the Examiner under 35 U.S.C. §112, second paragraph, as being indefinite. Specifically, there were two instances of “optionally contain one or more O, S or NR4 groups,” that were deemed to be unclear. Applicants hereby delete these wordings from the claims. Withdrawal of the rejection is respectfully requested.

### **Conclusion**

Having now responded to all the outstanding issues in the Office Action, Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100729-1P US.

Respectfully submitted,  
/Jianzhong SHEN, Reg.#48076/

---

Name: Jianzhong Shen  
Dated: Feb. 1, 2008  
Reg. No.: 48,076  
Phone No.: 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca  
1800 Concord Pike  
Wilmington  
DE-19850-5437